U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H20N2O3
Molecular Weight 264.3207
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORINOSTAT

SMILES

C(CCCC(=NO)O)CCC(=Nc1ccccc1)O

InChI

InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.

CNS Activity

Curator's Comment:: Vorinostat was shown to cross the blood-brain barrier in a mouse model of Huntington's disease. It inhibited the growth of GL26 GBM cells implanted into the brains of mice. Vorinostat treatment induced accumulation of acetylated histones H2B, H3, and H4 in patients with recurrent GBM.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.12 µM [IC50]
0.13 µM [IC50]
0.15 µM [IC50]
0.28 µM [IC50]
1.68 µM [IC50]
57.0 nM [IC50]
1.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zolinza

Approved Use

Treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

Launch Date

1.16000634E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μM
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
0.83 uM
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1.17 uM
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.5 μM × h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
4.59 uM*h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
5.59 uM*h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
1.94 h
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
2.3 h
400 mg 1 times / day steady, oral
dose: 400 mg
route of administration: oral
experiment type: steady
co-administered:
VORINOSTAT plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
29%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Disc. AE: Thrombocytopenia, Anemia...
Other AEs: Hypotension, Sepsis...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 3-4, 8%)
Anemia (grade 3-4, 17%)
Deep vein thrombosis (grade 3-4, 25%)
Pyrexia (grade 3-4, 25%)
Pulmonary embolism (grade 3-4, 17%)
Other AEs:
Hypotension (grade 3-4, 17%)
Sepsis (grade 3-4, 8%)
Fatigue (all grades, 27%)
Diarrhea (11%)
Nausea (8%)
Dysgeusia (11%)
Weight loss (3%)
Vomiting (11%)
Anorexia (3%)
Blood creatinine increased (8%)
Dehydration (5%)
Anemia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue grade 3, 1 patient
DLT, Disc. AE
250 mg 2 times / day multiple, oral
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 63 years (range: 38 - 74 years)
n = 5
Health Status: unhealthy
Condition: advanced multiple myeloma
Age Group: 63 years (range: 38 - 74 years)
Population Size: 5
Sources:
Diarrhea 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dysgeusia 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Vomiting 11%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anorexia 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Weight loss 3%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Dehydration 5%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Blood creatinine increased 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Nausea 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Fatigue all grades, 27%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Hypotension grade 3-4, 17%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Anemia grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pulmonary embolism grade 3-4, 17%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Deep vein thrombosis grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Pyrexia grade 3-4, 25%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Sepsis grade 3-4, 8%
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
Thrombocytopenia grade 3-4, 8%
Disc. AE
300 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, 69 years (range: 26.0 - 80.0 years)
n = 12
Health Status: unhealthy
Condition: cutaneous Tcell lymphoma
Age Group: 69 years (range: 26.0 - 80.0 years)
Sex: M+F
Population Size: 12
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no (co-administration study)
Comment: vorinostat has no inhibitory effect on the tranport of vinblastine
Page: 4, 6, 27
no [IC50 79.8 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
yes
yes
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.
2002 May 10
Anticancer drug shows promise against lupus.
2003 Apr 15
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
2003 Apr 15
Gateways to clinical trials.
2003 Dec
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
2003 Feb
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
2003 May 1
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
2003 Nov 15
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
2004 Apr
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
2004 Aug
Histone deacetylase inhibitors up-regulate the expression of tight junction proteins.
2004 Dec
Requirement of histone deacetylase activity for signaling by STAT1.
2004 Jul 16
Gateways to clinical trials.
2004 Jun
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
2004 Jun
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
2004 Jun 1
Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
2004 Jun 21
Role of oxidative enzymatic treatments on enzymatic hydrolysis of softwood.
2004 Jun 5
Silent advances.
2004 Mar
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
2004 Nov
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
2004 Sep
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
2004 Sep 15
Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.
2004 Sep 15
Histone deacetylase inhibitors in programmed cell death and cancer therapy.
2005 Apr
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
2005 Apr
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.
2005 Aug
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
2005 Dec
Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
2005 Feb 24
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
2005 Jan
Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
2005 Jan 17
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
2005 Jul
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
2005 Mar
4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp.
2005 Mar
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
2005 Mar
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
2005 Mar 1
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
2005 Mar 11
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
2005 Mar 15
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
2005 May
The role of histone acetylation in SMN gene expression.
2005 May 1
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
2005 Nov
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
2005 Nov 1
Crystal structure of a bacterial class 2 histone deacetylase homologue.
2005 Nov 18
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
2005 Oct
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
2005 Sep
Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.
2005 Sep 23
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
2006 Jan
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
2006 Jan
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
2006 Jan
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
2006 Jan 1
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
2006 Jul 1
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
2006 Mar
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
2006 Mar 3
Patents

Sample Use Guides

400 mg orally once daily with food. If patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.
Route of Administration: Oral
Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.
Name Type Language
VORINOSTAT
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
VORINOSTAT [MI]
Common Name English
NSC-759852
Code English
VORINOSTAT [ORANGE BOOK]
Common Name English
NSC-701852
Code English
N-HYDROXY-N'-PHENYLOCTANEDIAMIDE
Systematic Name English
NSC-748799
Code English
ZOLINZA
Brand Name English
VORINOSTAT [WHO-DD]
Common Name English
MK0683
Code English
VORINOSTAT [MART.]
Common Name English
MK-0683
Code English
VORINOSTAT [USAN]
Common Name English
OCTANEDIAMIDE, N-HYDROXY-N'-PHENYL-
Systematic Name English
VORINOSTAT [INN]
Common Name English
SUBEROYLANILIDE HYDROXAMIC ACID
Common Name English
VORINOSTAT [JAN]
Common Name English
VORINOSTAT [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 177203
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
WHO-VATC QL01XX38
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
EU-Orphan Drug EU/3/11/854
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
LIVERTOX 1040
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NCI_THESAURUS C1946
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NDF-RT N0000175588
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 540116
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
WHO-ATC L01XX38
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
NDF-RT N0000175071
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 174203
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
FDA ORPHAN DRUG 169503
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL98
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
DRUG CENTRAL
4124
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
CAS
149647-78-9
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
MERCK INDEX
M11502
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY Merck Index
HSDB
7930
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
PUBCHEM
5311
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
RXCUI
194337
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY RxNorm
FDA UNII
58IFB293JI
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
MESH
C111237
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
INN
8661
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
NCI_THESAURUS
C1796
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
IUPHAR
6852
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
WIKIPEDIA
VORINOSTAT
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
EPA CompTox
149647-78-9
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
EVMPD
SUB23356
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY
DRUG BANK
DB02546
Created by admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
PRIMARY